Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Board Changes and Delisting

8 Jul 2005 16:36

Eagerport Limited08 July 2005 Immediate Release 8 July 2005 This announcement is not for release, publication or distribution in or intoCanada, Australia or Japan. ANIXTER INTERNATIONAL INC and INFAST GROUP PLC INFAST BOARD CHANGES AND DELISTING Earlier today Eagerport Limited (a wholly-owned indirect subsidiary of AnixterInternational Inc.) announced that the Offer for the entire issued share capitalof Infast Group plc had been declared unconditional in all respects. Infast Board Changes Infast announces that, this afternoon, Dennis Letham, John Dul, Philippe Walpot,William Banks and Alexandra Holland joined the board of Infast. Dennis Lethamhas been appointed CEO of the Company, William Banks has been appointed asFinance Director, John Dul, Philippe Walpot and Alexandra Holland have beenappointed Executive Directors. Richard Seguin, Anthony Bruce, Graham Titcombe,Michael Parker, Robert Sternick, and John Kimber have resigned from the board. In connection with the appointments, there are no details that are required tobe disclosed by paragraph 9.6.13 of the Listing Rules of the UK ListingAuthority ("UKLA"). Delisting Application has been made by Infast to the UKLA for the cancellation of listingof Infast Shares on the Official List of the UKLA and to the London StockExchange for the cancellation of the admission to trading of Infast Shares onthe London Stock Exchange's market for listed securities. It is anticipatedthat cancellation of listing and admission to trading will take effect from 8August 2005, being 20 Business Days following the date of this announcement. Terms defined in the Offer Document have the same meanings in this announcement. Enquiries: Anixter Dennis Letham Tel: +1 224 521 8601KPMG Corporate Finance Charles E Cattaneo Tel: +44 (0) 121 232 3356Buchanan Communications Charles Ryland Tel: +44 (0) 20 7466 5000 James Strong Tel: +44 (0) 20 7466 5000 KPMG Corporate Finance, a division of KPMG LLP which is authorised and regulatedby the Financial Services Authority for investment business activities, isacting for Anixter and the Offeror as financial adviser in relation to the Offerand is not acting for any other person in relation to the Offer. KPMG CorporateFinance will not be responsible to anyone other than Anixter and the Offeror forproviding the protections afforded to its clients or for providing advice inrelation to the contents of this announcement or any transaction or arrangementreferred to herein. This announcement does not constitute an offer or invitation to purchase anysecurities or the solicitation of an offer to buy any securities, pursuant tothe Offer or otherwise. The Offer is being made solely pursuant to the OfferDocument and the Form of Acceptance accompanying the Offer Document, whichcontain the full terms and conditions of the Offer, including details of how theOffer may be accepted. The Offer is not being made, directly or indirectly, in or into, or by use ofthe mails of, or by any means or instrumentality (including, without limitation,facsimile transmission, electronic mail, telex or telephone) of interstate orforeign commerce of, or any facilities of a national securities exchange ofCanada, Australia, Japan or any jurisdiction where to do so would violate thelaws in that jurisdiction and the Offer will not be capable of acceptance by anysuch use, means, instrumentality or facility, directly or indirectly from orwithin Canada, Australia, Japan or any such jurisdiction. The Offer in the United States is being made solely by the Offeror, and neitherKPMG LLP, KPMG Corporate Finance, nor any of its respective affiliates, ismaking the Offer in the United States. The members of the Anixter Offer Committee accept responsibility for theinformation contained in this announcement relating to Anixter and the Offeror.To the best of the knowledge and belief of the members of the Anixter OfferCommittee (who have taken all reasonable care to ensure that such is the case),the information contained in this announcement for which they acceptresponsibility is in accordance with the facts and does not omit anything likelyto affect the import of such information. The Offeror Directors accept responsibility for the information contained inthis announcement relating to the Offeror. To the best of the knowledge andbelief of the Offeror Directors (who have taken all reasonable care to ensurethat such is the case), the information contained in this announcement for whichthey accept responsibility is in accordance with the facts and does not omitanything likely to affect the import of such information. END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20237:00 amRNSTransfer of ToxHub Platform and launch of Centrus®
11th May 20233:26 pmRNSHolding(s) in Company
11th May 20237:00 amRNSUS Government Contract Award
4th May 20235:07 pmRNSHolding(s) in Company
3rd May 20237:00 amRNSNotice of Results and Investor Presentation
2nd May 20234:13 pmRNSExercise of Options, Issue of Equity & TVR
14th Apr 20234:38 pmRNSHolding(s) in Company
13th Mar 20237:30 amRNSNo Exposure to Silicon Valley Bank
31st Jan 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSAppointment of Independent Non-Executive Director
5th Jan 20237:00 amRNSExercise of Options, Director/PDMR Dealing & TVR
22nd Dec 20227:00 amRNSContract Extension with Leading CRO
30th Nov 20225:48 pmRNSHolding(s) in Company
12th Oct 20227:00 amRNSExercise of Options, Issue of Equity and TVR
27th Sep 20227:01 amRNSHalf-year Report
27th Sep 20227:00 amRNSSettlement of Historical Licence Dispute
13th Sep 20227:00 amRNSNotice of Results and Investor Presentation
9th Sep 20223:49 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNS$12m five-year agreement with Leading CRO
4th Aug 20227:00 amRNSHalf Year Trading Update
29th Jun 20225:03 pmRNSHolding(s) in Company
9th Jun 20224:01 pmRNSResult of AGM
20th May 20224:31 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of AGM & Posting of Annual Report
3rd May 202212:00 pmRNSHolding(s) in Company
3rd May 20227:00 amRNSEuropean Medicines Agency Research Grant
26th Apr 20224:40 pmRNSSecond Price Monitoring Extn
26th Apr 20224:35 pmRNSPrice Monitoring Extension
26th Apr 202210:15 amRNSEarn Outs and Deferred Payments
26th Apr 20229:54 amRNSFinal Results
26th Apr 20227:00 amRNSAnnouncement re: full year results
20th Apr 20229:05 amRNSNotice of Results & Investor Presentation
15th Mar 20221:49 pmRNSGrant of PDMR Options
14th Mar 20225:29 pmRNSExercise of Options, Issue of Equity and TVR
14th Mar 202211:22 amRNSHolding(s) in Company
22nd Feb 202210:15 amRNSHolding(s) in Company
4th Feb 20228:08 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSTrading Update
11th Jan 20227:00 amRNSAppointment of Joint Broker
21st Dec 20217:00 amRNSH2 China Market Update
13th Dec 20214:55 pmRNSHolding(s) in Company
22nd Nov 20212:33 pmRNSHolding(s) in Company
22nd Nov 20217:00 amRNSNew In Silico Software Release
11th Oct 20213:15 pmRNSDirector/PDMR Shareholding
29th Sep 202110:34 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSDirectorate Change
28th Sep 20217:00 amRNSGrant of PDMR Options
27th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSNotice of Results and Investor Presentation
14th Sep 20217:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.